The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Tell us about the 5 key areas for quality improvement which you consider as having the greatest potential to improve the quality of care in this area ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on nemolizumab for treating moderate to severe atopic dermatitis in people 12 years ...

The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to change. You will receive your ...

Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there is ...

NICE leads the way in approving breakthrough treatment for multiple myeloma People in England will become the first in the world to receive belantamab mafodotin for this indication following our ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...

NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin with bortezomib and dexamethasone within its marketing authorisation for treating relapsed or refractory ...

Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. Last reviewed: 24 June 2025 Next review: ...